Remnant cholesterol as a cause of ischemic heart disease: Evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment

Pharmacology and Therapeutics

Volumn 141, Issue 3, 2014, Pages 358-367

  Varbo, Anette ^a,b   Benn, Marianne ^a,b   Nordestgaard, Brge G ^a,b,c  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c FREDERIKSBERG HOSPITAL   (Denmark)

Author keywords

Atherosclerosis; Cardiovascular disease; Causal; Cholesterol; Lipoprotein; Remnants

Indexed keywords

CHOLESTEROL; FISH OIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIPOMERSEN; NICOTINIC ACID; OMEGA 3 FATTY ACID; TRIACYLGLYCEROL;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DISEASE ASSOCIATION; EXPERIMENTAL STUDY; GENETIC VARIABILITY; HIGH RISK PATIENT; HUMAN; IN VITRO STUDY; INFLAMMATION; ISCHEMIC HEART DISEASE; NONHUMAN; OBSERVATIONAL STUDY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CAUSAL; CHOLESTEROL; HDL; HIGH-DENSITY LIPOPROTEIN; IDL; IHD; INTERMEDIATE-DENSITY LIPOPROTEIN; ISCHEMIC HEART DISEASE; LDL; LDL RECEPTOR-RELATED PROTEIN; LIPOPROTEIN; LOW-DENSITY LIPOPROTEIN; LRP; REMNANTS; VERY-LOW-DENSITY LIPOPROTEIN; VLDL;

ANIMALS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL, LDL; HUMANS; INFLAMMATION; LIPOPROTEINS, HDL; MYOCARDIAL ISCHEMIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TRIGLYCERIDES;

EID: 84892366435     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2013.11.008     Document Type: Review

References (110)

1. A. Alipour, A.J. Van Oostrom, A. Izraeljan, C. Verseyden, J.M. Collins, and K.N. Frayn et al. Leukocyte activation by triglyceride-rich lipoproteins Arterioscler Thromb Vasc Biol 28 2008 792 797
2. M.A. Austin Plasma triglyceride and coronary heart disease Arterioscler Thromb 11 1991 2 14
3. S. Bansal, J.E. Buring, N. Rifai, S. Mora, F.M. Sacks, and P.M. Ridker Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women JAMA 298 2007 309 316
4. P.J. Barter, M. Caulfield, M. Eriksson, S.M. Grundy, J.J. Kastelein, and M. Komajda et al. Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2007 2109 2122
5. H.E. Bays, R.A. Braeckman, C.M. Ballantyne, J.J. Kastelein, J.D. Otvos, and W.G. Stirtan et al. Icosapent ethyl, a pure EPA omega-3 fatty acid: Effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study) J Clin Lipidol 6 2012 565 572
6. P. Benlian, J.L. De Gennes, L. Foubert, H. Zhang, S.E. Gagne, and M. Hayden Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene N Engl J Med 335 1996 848 854
7. W.E. Boden, J.L. Probstfield, T. Anderson, B.R. Chaitman, P. Desvignes-Nickens, and K. Koprowicz et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
8. J.D. Brunzell, and S.S. Deeb Familial lipoprotein lipase deficiency, Apo C-II deficiency, and hepatic lipase deficiency C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle, The metabolic and molecular bases of inherited diseases 8th ed. 2001 Mc-Graw-Hill, Medical Publishing Division 2789 2816
9. P.L. Canner, K.G. Berge, N.K. Wenger, J. Stamler, L. Friedman, and R.J. Prineas et al. Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin J Am Coll Cardiol 8 1986 1245 1255
10. C.P. Cannon, S. Shah, H.M. Dansky, M. Davidson, E.A. Brinton, and A.M. Gotto et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease N Engl J Med 363 2010 2406 2415
11. L.A. Carlson, and G. Rosenhamer Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid Acta Med Scand 223 1988 405 418
12. M. Casula, D. Soranna, A.L. Catapano, and G. Corrao Long-term effect of high dose omega-3 fatty acid supplementation for secondary prevention of cardiovascular outcomes: A meta-analysis of randomized, double blind, placebo controlled trials Atheroscler Suppl 14 2013 243 251
13. M.J. Chapman, H.N. Ginsberg, P. Amarenco, F. Andreotti, J. Boren, and A.L. Catapano et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: Evidence and guidance for management Eur Heart J 32 2011 1345 1361
14. Clofibrate, niacin in coronary heart disease JAMA 231 1975 360 381
15. M. Cuchel, L.T. Bloedon, P.O. Szapary, D.M. Kolansky, M.L. Wolfe, and A. Sarkis et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia N Engl J Med 356 2007 148 156
16. M. Cuchel, E.A. Meagher, T.H. du Toit, D.J. Blom, A.D. Marais, and R.A. Hegele et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: A single-arm, open-label, phase 3 study Lancet 381 2013 40 46
17. M.J. Davies Stability and instability: Two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995 Circulation 94 1996 2013 2020
18. S. Devaraj, G. Vega, R. Lange, S.M. Grundy, and I. Jialal Remnant-like particle cholesterol levels in patients with dysbetalipoproteinemia or coronary artery disease Am J Med 104 1998 445 450
19. E. Di Angelantonio, N. Sarwar, P. Perry, S. Kaptoge, K.K. Ray, and A. Thompson et al. Major lipids, apolipoproteins, and risk of vascular disease JAMA 302 2009 1993 2000
20. M. Eriksson, M. Larsson, R. Caraballo, P.A. Enquist, M. Elofsson, and G. Olivecrona Novel small molecule lipoprotein lipase activator LP071 improves plasma lipid parameters in vivo Paper presented at the 81st Annual Congress of the European Atherosclerosis Society, Lyon 2-5 June 2013 2013
21. E. Falk, P.K. Shah, and V. Fuster Coronary plaque disruption Circulation 92 1995 657 671
22. J.J. Freiberg, A. Tybjaerg-Hansen, J.S. Jensen, and B.G. Nordestgaard Nonfasting triglycerides and risk of ischemic stroke in the general population JAMA 300 2008 2142 2152
23. R. Frikke-Schmidt, B.G. Nordestgaard, B. Agerholm-Larsen, P. Schnohr, and A. Tybjærg-Hansen Context-dependent and invariant associations between lipids, lipoproteins, and apolipoproteins and apolipoprotein E genotype J Lipid Res 41 2000 1812 1822
24. H. Fukushima, K. Kugiyama, S. Sugiyama, O. Honda, S. Koide, and S. Nakamura et al. Comparison of remnant-like lipoprotein particles in postmenopausal women with and without coronary artery disease and in men with coronary artery disease Am J Cardiol 88 2001 1370 1373
25. H. Fukushima, S. Sugiyama, O. Honda, S. Koide, S. Nakamura, and T. Sakamoto et al. Prognostic value of remnant-like lipoprotein particle levels in patients with coronary artery disease and type II diabetes mellitus J Am Coll Cardiol 43 2004 2219 2224
26. D. Gaudet, J. Methot, and J. Kastelein Gene therapy for lipoprotein lipase deficiency Curr Opin Lipidol 23 2012 310 320
27. C. Giannattasio, A. Zoppo, G. Gentile, M. Failla, A. Capra, and F.M. Maggi et al. Acute effect of high-fat meal on endothelial function in moderately dyslipidemic subjects Arterioscler Thromb Vasc Biol 25 2005 406 410
28. J.W. Gofman, M. Hanig, J.B. Jones, M.A. Lauffer, E.Y. Lawry, and L.A. Lewis et al. Evaluation of serum lipoprotein and cholesterol measurements as predictors of clinical complications of atherosclerosis; report of a cooperative study of lipoproteins and atherosclerosis Circulation 14 1956 691 742
29. T. Gotoda, K. Shirai, T. Ohta, J. Kobayashi, S. Yokoyama, and S. Oikawa et al. Diagnosis and management of type I and type V hyperlipoproteinemia J Atheroscler Thromb 19 2012 1 12
30. A.M. Gotto Jr., and J.E. Moon Recent clinical studies of the effects of lipid-modifying therapies Am J Cardiol 110 2012 15A 26A
31. A.M. Gotto Jr., and J.E. Moon Pharmacotherapies for lipid modification: Beyond the statins Nat Rev Cardiol 10 2013 560 570
32. M.J. Graham, R.G. Lee, T.A. Bell III, W. Fu, A.E. Mullick, and V.J. Alexander et al. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans Circ Res 112 2013 1479 1490
33. P.J. Grant Diabetes mellitus as a prothrombotic condition J Intern Med 262 2007 157 172
34. S.M. Grundy, J.I. Cleeman, C.N. Merz, H.B. Brewer Jr., L.T. Clark, and D.B. Hunninghake et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239
35. H. Hanada, S. Mugii, M. Okubo, I. Maeda, K. Kuwayama, and Y. Hidaka et al. Establishment of chemiluminescence enzyme immunoassay for apolipoprotein B-48 and its clinical applications for evaluation of impaired chylomicron remnant metabolism Clin Chim Acta 413 2012 160 165
36. R.J. Havel Remnant lipoproteins as therapeutic targets Curr Opin Lipidol 11 2000 615 620
37. R.J. Havel Triglyceride-rich lipoproteins and plasma lipid transport Arterioscler Thromb Vasc Biol 30 2010 9 19
38. R.J. Havel, and J.P. Kane Introduction: Structure and metabolism of plasma lipoproteins C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle, The metabolic and molecular bases of inherited diseases 8th ed. 2001 Mc-Graw-Hill, Medical Publishing Division 2705 2716
39. R. Haynes, L. Jiang, J.C. Hopewell, J. Li, F. Chen, and S. Parish et al. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: Trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment Eur Heart J 34 2013 1279 1291
40. R.A. Hegele, M.R. Ban, N. Hsueh, B.A. Kennedy, H. Cao, and G.Y. Zou et al. A polygenic basis for four classical Fredrickson hyperlipoproteinemia phenotypes that are characterized by hypertriglyceridemia Hum Mol Genet 18 2009 4189 4194
41. K. Higashi, T. Ito, K. Nakajima, A. Yonemura, H. Nakamura, and F. Ohsuzu Remnant-like particles cholesterol is higher in diabetic patients with coronary artery disease Metabolism 50 2001 1462 1465
42. M. Hiki, K. Shimada, H. Ohmura, T. Kiyanagi, A. Kume, and K. Sumiyoshi et al. Serum levels of remnant lipoprotein cholesterol and oxidized low-density lipoprotein in patients with coronary artery disease J Cardiol 53 2009 108 116
43. J.E. Hokanson, and M.A. Austin Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies J Cardiovasc Risk 3 1996 213 219
44. P.N. Hopkins, L.L. Wu, S.C. Hunt, and E.A. Brinton Plasma triglycerides and type III hyperlipidemia are independently associated with premature familial coronary artery disease J Am Coll Cardiol 45 2005 1003 1012
45. HPS2-THRIVE press release on preliminary results http://www.thrivestudy. org/press-release.htm 2013
46. C. Imke, B.L. Rodriguez, J.S. Grove, J.R. McNamara, C. Waslien, and A.R. Katz et al. Are remnant-like particles independent predictors of coronary heart disease incidence? The Honolulu Heart study Arterioscler Thromb Vasc Biol 25 2005 1718 1722
47. T. Inoue, T. Uchida, H. Kamishirado, K. Takayanagi, T. Hayashi, and S. Morooka et al. Remnant-like lipoprotein particles as risk factors for coronary artery disease in elderly patients Horm Metab Res 36 2004 298 302
48. C.T. Johansen, and R.A. Hegele Genetic bases of hypertriglyceridemic phenotypes Curr Opin Lipidol 22 2011 247 253
49. C.T. Johansen, S. Kathiresan, and R.A. Hegele Genetic determinants of plasma triglycerides J Lipid Res 52 2011 189 206
50. C.T. Johansen, J. Wang, M.B. Lanktree, A.D. McIntyre, M.R. Ban, and R.A. Martins et al. An increased burden of common and rare lipid-associated risk alleles contributes to the phenotypic spectrum of hypertriglyceridemia Arterioscler Thromb Vasc Biol 31 2011 1916 1926
51. A.B. Jorgensen, R. Frikke-Schmidt, A.S. West, P. Grande, B.G. Nordestgaard, and A. Tybjaerg-Hansen Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction Eur Heart J 34 2013 1826 1833
52. M. Jun, C. Foote, J. Lv, B. Neal, A. Patel, and S.J. Nicholls et al. Effects of fibrates on cardiovascular outcomes: A systematic review and meta-analysis Lancet 375 2010 1875 1884
53. F. Karpe, S. Boquist, R. Tang, G.M. Bond, F.U. De, and A. Hamsten Remnant lipoproteins are related to intima-media thickness of the carotid artery independently of LDL cholesterol and plasma triglycerides J Lipid Res 42 2001 17 21
54. S. Kathiresan, O. Melander, C. Guiducci, A. Surti, N.P. Burtt, and M.J. Rieder et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans Nat Genet 40 2008 189 197
55. E. Kiss-Toth, S.M. Bagstaff, H.Y. Sung, V. Jozsa, C. Dempsey, and J.C. Caunt et al. Human tribbles, a protein family controlling mitogen-activated protein kinase cascades J Biol Chem 279 2004 42703 42708
56. H.P. Kohler, and P.J. Grant Plasminogen-activator inhibitor type 1 and coronary artery disease N Engl J Med 342 2000 1792 1801
57. G.D. Kolovou, D.P. Mikhailidis, J. Kovar, D. Lairon, B.G. Nordestgaard, and T.C. Ooi et al. Assessment and clinical relevance of non-fasting and postprandial triglycerides: An expert panel statement Curr Vasc Pharmacol 9 2011 258 270
58. F. Kronenberg, and G. Utermann Lipoprotein(a): Resurrected by genetics J Intern Med 273 2013 6 30
59. K. Kugiyama, H. Doi, K. Takazoe, H. Kawano, H. Soejima, and Y. Mizuno et al. Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease Circulation 99 1999 2858 2860
60. S.M. Kwak, S.K. Myung, Y.J. Lee, and H.G. Seo Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: A meta-analysis of randomized, double-blind, placebo-controlled trials Arch Intern Med 172 2012 686 694
61. S. Lamon-Fava, D.M. Herrington, D.M. Reboussin, M. Sherman, K.V. Horvath, and L.A. Cupples et al. Plasma levels of HDL subpopulations and remnant lipoproteins predict the extent of angiographically-defined coronary artery disease in postmenopausal women Arterioscler Thromb Vasc Biol 28 2008 575 579
62. A. Langsted, J.J. Freiberg, A. Tybjaerg-Hansen, P. Schnohr, G.B. Jensen, and B.G. Nordestgaard Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: The Copenhagen City Heart Study with 31 years of follow-up J Intern Med 270 2011 65 75
63. P.M. Lavigne, and R.H. Karas The current state of niacin in cardiovascular disease prevention: A systematic review and meta-regression J Am Coll Cardiol 61 2013 440 446
64. P. Lee, and R.A. Hegele Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia Expert Opin Investig Drugs 22 2013 1411 1423
65. J.P. MacArthur, J.R. Bishop, K.I. Stanford, L. Wang, A. Bensadoun, and J.L. Witztum et al. Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members J Clin Invest 117 2007 153 164
66. H. Masuoka, K. Ishikura, S. Kamei, T. Obe, T. Seko, and K. Okuda et al. Predictive value of remnant-like particles cholesterol/high-density lipoprotein cholesterol ratio as a new indicator of coronary artery disease Am Heart J 136 1998 226 230
67. H. Masuoka, S. Kamei, M. Ozaki, A. Kawasaki, U. Shintani, and M. Ito et al. Predictive value of remnant-like particle cholesterol as an indicator of coronary artery stenosis in patients with normal serum triglyceride levels Intern Med 39 2000 540 546
68. H. Masuoka, S. Kamei, H. Wagayama, M. Ozaki, A. Kawasaki, and T. Tanaka et al. Association of remnant-like particle cholesterol with coronary artery disease in patients with normal total cholesterol levels Am Heart J 139 2000 305 310
69. J.R. McNamara, P.K. Shah, K. Nakajima, L.A. Cupples, P.W. Wilson, and J.M. Ordovas et al. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: Results from the Framingham Heart Study Atherosclerosis 154 2001 229 236
70. K. Miwa, T. Makita, K. Ishii, N. Okuda, and A. Taniguchi High remnant lipoprotein levels in patients with variant angina Clin Cardiol 27 2004 338 342
71. S. Mora, N. Rifai, J.E. Buring, and P.M. Ridker Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events Circulation 118 2008 993 1001
72. M.P. Moyer, R.P. Tracy, P.B. Tracy, C. van't Veer, C.E. Sparks, and K.G. Mann Plasma lipoproteins support prothrombinase and other procoagulant enzymatic complexes Arterioscler Thromb Vasc Biol 18 1998 458 465
73. K. Nakajima, T. Nakano, and A. Tanaka The oxidative modification hypothesis of atherosclerosis: The comparison of atherogenic effects on oxidized LDL and remnant lipoproteins in plasma Clin Chim Acta 367 2006 36 47
74. K. Nakajima, T. Nakano, Y. Tokita, T. Nagamine, A. Inazu, and J. Kobayashi et al. Postprandial lipoprotein metabolism: VLDL vs chylomicrons Clin Chim Acta 412 2011 1306 1318
75. K. Nakajima, T. Saito, A. Tamura, M. Suzuki, T. Nakano, and M. Adachi et al. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels Clin Chim Acta 223 1993 53 71
76. T. Nakamura, H. Takano, K. Umetani, K. Kawabata, J.E. Obata, and Y. Kitta et al. Remnant lipoproteinemia is a risk factor for endothelial vasomotor dysfunction and coronary artery disease in metabolic syndrome Atherosclerosis 181 2005 321 327
77. S.J. Nicholls, H.B. Brewer, J.J. Kastelein, K.A. Krueger, M.D. Wang, and M. Shao et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: A randomized controlled trial JAMA 306 2011 2099 2109
78. B.G. Nordestgaard, M. Benn, P. Schnohr, and A. Tybjaerg-Hansen Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women JAMA 298 2007 299 308
79. B.G. Nordestgaard, M.J. Chapman, K. Ray, J. Boren, F. Andreotti, and G.F. Watts et al. Lipoprotein(a) as a cardiovascular risk factor: Current status Eur Heart J 31 2010 2844 2853
80. B.G. Nordestgaard, and J.J. Freiberg Clinical relevance of non-fasting and postprandial hypertriglyceridemia and remnant cholesterol Curr Vasc Pharmacol 9 2011 281 286
81. B.G. Nordestgaard, A. Langsted, and J.J. Freiberg Nonfasting hyperlipidemia and cardiovascular disease Curr Drug Targets 10 2009 328 335
82. B.G. Nordestgaard, S. Stender, and K. Kjeldsen Reduced atherogenesis in cholesterol-fed diabetic rabbits. Giant lipoproteins do not enter the arterial wall Arteriosclerosis 8 1988 421 428
83. B.G. Nordestgaard, A. Tybjaerg-Hansen, and B. Lewis Influx in vivo of low density, intermediate density, and very low density lipoproteins into aortic intimas of genetically hyperlipidemic rabbits. Roles of plasma concentrations, extent of aortic lesion, and lipoprotein particle size as determinants Arterioscler Thromb 12 1992 6 18
84. B.G. Nordestgaard, R. Wootton, and B. Lewis Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media Arterioscler Thromb Vasc Biol 15 1995 534 542
85. B.G. Nordestgaard, and D.B. Zilversmit Large lipoproteins are excluded from the arterial wall in diabetic cholesterol-fed rabbits J Lipid Res 29 1988 1491 1500
86. K. Oi, H. Shimokawa, Y. Hirakawa, H. Tashiro, R. Nakaike, and T. Kozai et al. Postprandial increase in plasma concentrations of remnant-like particles: An independent risk factor for restenosis after percutaneous coronary intervention J Cardiovasc Pharmacol 44 2004 66 73
87. T.C. Ooi, and B.G. Nordestgaard Methods to study postprandial lipemia Curr Vasc Pharmacol 9 2011 302 308
88. F.J. Raal, R.D. Santos, D.J. Blom, A.D. Marais, M.J. Charng, and W.C. Cromwell et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: A randomised, double-blind, placebo-controlled trial Lancet 375 2010 998 1006
89. I. Ramasamy Recent advances in physiological lipoprotein metabolism Clin Chem Lab Med 12 2013 1 33
90. J.H. Rapp, A. Lespine, R.L. Hamilton, N. Colyvas, A.H. Chaumeton, and J. Tweedie-Hardman et al. Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque Arterioscler Thromb 14 1994 1767 1774
91. E.C. Rizos, E.E. Ntzani, E. Bika, M.S. Kostapanos, and M.S. Elisaf Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: A systematic review and meta-analysis JAMA 308 2012 1024 1033
92. F.M. Sacks, V.J. Carey, and J.C. Fruchart Combination lipid therapy in type 2 diabetes N Engl J Med 363 2010 692 694
93. K. Sakata, N. Miho, M. Shirotani, H. Yoshida, Y. Takada, and A. Takada Remnant-like particle cholesterol is a major risk factor for myocardial infarction in vasospastic angina with nearly normal coronary artery Atherosclerosis 136 1998 225 231
94. A. Sambola, J. Osende, J. Hathcock, M. Degen, Y. Nemerson, and V. Fuster et al. Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity Circulation 107 2003 973 977
95. G.G. Schwartz, A.G. Olsson, M. Abt, C.M. Ballantyne, P.J. Barter, and J. Brumm et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome N Engl J Med 367 2012 2089 2099
96. M. Shaikh, R. Wootton, B.G. Nordestgaard, P. Baskerville, J.S. Lumley, and A.E. La Ville et al. Quantitative studies of transfer in vivo of low density, Sf 12-60, and Sf 60-400 lipoproteins between plasma and arterial intima in humans Arterioscler Thromb 11 1991 569 577
97. J. Song, H. Park, S.H. Hong, H.K. Lee, Y.B. Park, and J.Q. Kim Remnant-like particle cholesterol levels in Korean patients with coronary artery disease and non-insulin dependent diabetes mellitus Clin Chem Lab Med 38 2000 427 432
98. A.F. Stalenhoef, and J. de Graaf Association of fasting and nonfasting serum triglycerides with cardiovascular disease and the role of remnant-like lipoproteins and small dense LDL Curr Opin Lipidol 19 2008 355 361
99. S. Takeichi, N. Yukawa, Y. Nakajima, M. Osawa, T. Saito, and Y. Seto et al. Association of plasma triglyceride-rich lipoprotein remnants with coronary atherosclerosis in cases of sudden cardiac death Atherosclerosis 142 1999 309 315
100. T.M. Teslovich, K. Musunuru, A.V. Smith, A.C. Edmondson, I.M. Stylianou, and M. Koseki et al. Biological, clinical and population relevance of 95 loci for blood lipids Nature 466 2010 707 713
101. H.J. Ting, J.P. Stice, U.Y. Schaff, D.Y. Hui, J.C. Rutledge, and A.A. Knowlton et al. Triglyceride-rich lipoproteins prime aortic endothelium for an enhanced inflammatory response to tumor necrosis factor-alpha Circ Res 100 2007 381 390
102. A. Varbo, M. Benn, A. Tybjaerg-Hansen, P. Grande, and B.G. Nordestgaard TRIB1 and GCKR polymorphisms, lipid levels, and risk of ischemic heart disease in the general population Arterioscler Thromb Vasc Biol 31 2011 451 457
103. A. Varbo, M. Benn, A. Tybjaerg-Hansen, A.B. Jorgensen, R. Frikke-Schmidt, and B.G. Nordestgaard Remnant cholesterol as a causal risk factor for ischemic heart disease J Am Coll Cardiol 61 2013 427 436
104. A. Varbo, M. Benn, A. Tybjaerg-Hansen, and B.G. Nordestgaard Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, while elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation Circulation 128 2013 1298 1309
105. A. Varbo, B.G. Nordestgaard, A. Tybjaerg-Hansen, P. Schnohr, G.B. Jensen, and M. Benn Nonfasting triglycerides, cholesterol, and ischemic stroke in the general population Ann Neurol 69 2011 628 634
106. L. Wang, R. Gill, T.L. Pedersen, L.J. Higgins, J.W. Newman, and J.C. Rutledge Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation J Lipid Res 50 2009 204 213
107. C.J. Willer, S. Sanna, A.U. Jackson, A. Scuteri, L.L. Bonnycastle, and R. Clarke et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease Nat Genet 40 2008 161 169
108. G. Yuan, K.Z. Al-Shali, and R.A. Hegele Hypertriglyceridemia: Its etiology, effects and treatment CMAJ 176 2007 1113 1120
109. X.Y. Zheng, and L. Liu Remnant-like lipoprotein particles impair endothelial function: Direct and indirect effects on nitric oxide synthase J Lipid Res 48 2007 1673 1680
110. D.B. Zilversmit Atherogenesis: A postprandial phenomenon Circulation 60 1979 473 485